Skip to main content
Download PDF

Non-linear relationship between TSH and psychotic symptoms on first episode and drug naïve major depressive disorder patients: a large sample sized cross-sectional study in China

BMC Psychiatry volume 24, Article number: 413 (2024) Cite this article

Abstract

Introduction

Psychotic depression (PD) is characterized by the co-occurrence of emotional dysfunction and psychotic symptoms such as delusions and hallucinations with poor clinical outcomes. TSH may involve in the development of PD. This study aims to explore relationship between TSH and PD.

Methods

A total of 1718 outpatients diagnosed as FEDN MDD were recruited in this study. The relationship between PD and TSH was evaluated using multivariable binary logistic regression analysis. To assess the presence of non-linear associations, a two-piecewise linear regression model was employed. Furthermore, interaction and stratified analyses were conducted with respect to sex, education, marital status, comorbid anxiety, and suicide attempt.

Results

Multivariable logistic regression analysis revealed that TSH was positively associated with the risk of PD after adjusting for confounders (OR = 1.26, 95% CI: 1.11 to 1.43; p < 0.05). Smoothing plots showed a nonlinear relationship between TSH and PD, with the inflection point of TSH being 4.94 mIU/L. On the right of the inflection point, for each unit increase in serum TSH level on the right side of the inflection point, the probability of PD increased substantially by 47% (OR = 1.47, 95% CI: 1.25 to 1.73, p < 0.001), while no significant association was observed on the left side of the inflection point (OR = 0.87, 95% CI: 0.67 to 1.14, p = 0.32).

Conclusion

Our investigation showed a nonlinear TSH-PD relationship in FEDN MDD patients, thus contributing to effective intervention strategies for psychotic symptoms in depression patients.

Peer Review reports

Introduction

Major depressive disorder (MDD) ranks consistently among the top ten causes of years lived with disability (YLDs) in every country [1], and it is the most prevalent mood disorder in China [2]. Psychotic depression (PD) is characterized by the co-occurrence of emotional dysfunction and psychotic symptoms such as delusions and hallucinations [3]. Previous research has indicated a high prevalence of PD among patients with MDD, with rates ranging from 5.6 to 45% [4,5,6,7]. PD patients, in comparison to those with non-psychotic depression (NPD), demonstrate poorer clinical outcomes [8], including higher mortality rates [9,10,11] and increased incidence of suicide attempts [10].

Researchers suggested that the presence of psychotic symptomatology in depression is functionally and etiologically highly relevant [12]. Within this framework, thyroid hormones have emerged as key players in this complex relationship [13]. MDD patients with thyroid dysfunction comorbid hypothyroidism were more likely to present psychotic features and experience more severe depression [14]. Furthermore, a body of prior research has consistently reported associations between aberrations in the hypothalamus-pituitary-thyroid (HPT) axis and the manifestation of both psychotic symptoms [15,16,17,18] and depression [19,20,21,22].

Thyroid-stimulating hormone (TSH), synthesized in the pituitary gland, offers a more sensitive reflection of HPT axis function compared to other hormones [23]. For instance, in subclinical thyroid disorders, thyroid hormone levels are still in normal range, but with TSH rising or declining, we can predict potential disturbance of thyroid function and apply early intervention at subclinical stage for better clinical outcome. Though previous investigations have focused on relationship between psychotic symptoms and thyroid function, no consistent consensus has been reached thus far [15, 24,25,26,27,28,29]. Besides, a limited number of studies have focused on their relationship among MDD patients [30,31,32]. Consequently, this study delves into the specific association between TSH and PD. Furthermore, it is worth highlighting that our research exclusively recruited first-episode and drug naïve (FEDN) MDD patients, effectively minimizing the potential confounding effects of medication [33]. Moreover, considering the possibility of a non-linear relationship between TSH and PD, this study employs advanced statistical analyses to better elucidate their correlations.

Methods

Subjects

From 2015 to 2017, this cross-sectional study included 1718 outpatients from the First Hospital of Shanxi Medical University.

The study inclusion criteria were: (1) Han nationality; (2) age between 18 and 60 years; (3) a diagnosis of MDD based on DSM-IV conducted by two trained clinical psychiatrists; (4) depressive symptoms were first-episode without any prior antidepressant, antipsychotic; (5) a duration of illness no longer than 24 months; (6) a minimum score of 24 on the 17-item Hamilton Rating Scale for Depression (HAMD-17); (7) no previous thyroxine therapy, or any specific medications. Exclusion criteria were: (1) having a severe physical disease, such as organic brain diseases or severe infection; (2) presence of any other major SCID-based DSM-IV Axis I disorder; (3) pregnancy or lactation; (4) alcohol or substance dependence or abuse except for tobacco smoking [34].

All participants voluntarily agreed to participate in the study and provided written informed consent prior to enrollment. The study protocol was approved by the medical ethics committee at the First Hospital of Shanxi Medical University.

Socio-demographic characteristics

Well-trained researchers collected a range of socio-demographic characteristics from the participants, including age, gender, age at onset, illness duration, marital status, education level, systolic blood pressure (SBP), diastolic blood pressure (DBP), and body mass index (BMI).

Clinical measures

The assessment of depression severity in this study was conducted using the 17-item Hamilton Depression Scale (HAMD), while anxiety severity was measured using the 14-item Hamilton Anxiety Rating Scale (HAMA). To ensure unbiased data collection, two qualified psychiatrists, unaware of participants’ clinical conditions, collected the aforementioned information through the Structured Clinical Interview for DSM Disorders (SCID). The inter-rater reliability of the HAMD, HAMA, and PANSS-P total scores was assessed through repetitive evaluations, resulting in observer correlation coefficients exceeding 0.8. Consistent with previous studies [35, 36], a cutoff point 15 for PANSS-P was used to identify PD in FEDN MDD patients. Suicide attempt, which was defined as self-injurious behavior, with an intention to end one’s life, but not resulting in death, was evaluated through a face-to-face interview with subjects and/or their family members by question “Have you (he or she) ever attempted suicide in your (or the patient’s) lifetime?” Interviewees responded “yes” to this inquiry were regarded as suicide attempters.

Blood sample

Following an overnight fast, blood samples were collected from the participants between 6:00 and 8:00 a.m. and promptly sent for testing before 11 a.m. The measurement of serum TSH levels was performed by the hospital laboratory center using the Roche C6000 Electrochemiluminescence Immunoassay Analyzer (Roche Diagnostics, Indianapolis, IN, USA). The established normal range for TSH was 0.27–4.20 mIU/L. Additionally, various other blood biomarkers, including free triiodothyronine (FT3), free thyroxine (FT4), thyroid peroxidase antibody (TPOAb), anti-thyroglobulin (TgAb), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), were all measured on the same day. To facilitate analysis, the patients were divided into three groups of equal size based on their serum TSH levels, namely low, middle, and high groups [34].

Statistical analysis

Continuous variables were presented according to their distribution. Non-normally distributed data were reported as the median with interquartile range (IQR), while normally distributed variables were expressed as the mean with standard deviation (SD). Categorical variables were presented as frequencies and percentages. To assess differences between the tertile groups of serum TSH levels, a one-way ANOVA test, Kruskal-Wallis H test, or χ2 test was employed. The linear relationship between the serum TSH levels and psychotic symptoms was estimated using logistic regression models, and the serum TSH level was examined as both continuous and categorical variables based on tertiles. Unadjusted and adjusted odds ratios (ORs) were presented with 95% confidence intervals (CIs). Sensitivity analyses were conducted to ensure the robustness of the data analysis. In order to determine a p-value for trend, the serum TSH level was transformed into a categorical variable. The variance inflation factor (VIF) was used to assess multicollinearity among independent variables, with covariates having VIF values above 5.0 excluded from the final model. Potential confounders were selected if they changed the estimates of serum TSH level on PD by more than 10% or had a p-value of less than 0.10 in univariable analysis. Three models were constructed to verify the stability of the results: an unadjusted model, Model I adjusted for sex and age, and Model II adjusted for age, gender, education, HAMA, HAMD, TGAb, TPOAb, TC, TG, FBG, HDL-c, LDL-c, SBP, and DBP. The non-linear relationship between serum TSH levels and PD was assessed using smoothing plots, and the threshold impact suggested by the smoothing plot was investigated using a two-piecewise linear regression model based on the generalized estimating equation (GEE) and an inflection point was calculated using a recursive algorithm. Stratified analyses were performed based on sex, education, marital status, comorbid anxiety, and suicide attempt. The interaction effects within various subgroups variables were evaluated using the log-likelihood ratio test. All statistical analyses were performed using the R software packages (http://www.r-project.org, The R Foundation) and EmpowerStats (http://www.empowerstats.com, X&Y Solution, Inc., Boston, Massachusetts, United States). GraphPad Prism 8.0 was used to create the visualizations. Statistical significance was defined as two tails of p < 0.05.

Results

Baseline characteristics

Table 1 lists the participant characteristics categorized based on tertiiles of serum TSH level. Significant correlations between serum TSH level tertiles and several variables, including age, duration of illness, age at onset, HAMD, HAMA, TGAb, TPOAb, FBG, TC, TG, HDL-c, LDL-c, BMI, SBP, DBP, comorbid anxiety, psychotic symptoms and suicide attempt (all p < 0.05), were found. Figure 1 demonstrates the distribution of TSH in FEDN MDD patients with or without psychotic symptoms.

Table 1 Socio-demographical and clinical characteristics of the participants
Full size table
Fig. 1
figure 1

Distribution of TSH in FEDN MDD patients with or without psychotic symptoms

Full size image

Associations between serum TSH level and PD

In the fully adjusted analysis (Table 2), a higher serum TSH level was substantially linked to a higher risk of PD, according to the fully adjusted data (OR = 1.26, 95% CI: 1.11 to 1.43; p < 0.05).

Table 2 Relationship between TSH and psychotic symptoms in different models
Full size table

To further explore the relationship between serum TSH level and PD, generalized additive models were employed and depicted in Fig. 2. The analysis revealed a non-linear association between serum TSH level and PD, with a significant p-value for non-linearity (< 0.05). Subsequently, a two-segment logistic regression model was utilized to identify an inflection point at a serum TSH level of 4.94 mIU/L.

Fig. 2
figure 2

The relationship between TSH and the probability of psychotic symptoms. A nonlinear relationship between TSH and the probability of psychotic symptoms was observed after adjusting for age, gender, education, HAMA, HAMD, TGAb, TPOAb, TC, TG, FBG, HDL-c, LDL-c, SBP, and DBP

Full size image

The results from the generalized additive models, as shown in Fig. 2, demonstrated a non-linear pattern between serum TSH level and PD, with a significant p-value for non-linearity (< 0.05). The two-segment logistic regression model indicated that for each unit increase in serum TSH level on the right side of the inflection point, the probability of PD increased substantially by 47% (OR = 1.47, 95% CI: 1.25 to 1.73, p < 0.001). However, on the left side of the inflection point, there was no significant evidence of a relationship between serum TSH level and PD (OR = 0.87, 95% CI: 0.67 to 1.14, p = 0.32), as presented in Table 3. Specifically, among the study participants, 842 individuals had a serum TSH level equal to or greater than 4.94 mIU/L, while 876 individuals had a serum TSH level less than 4.94 mIU/L.

Table 3 The results of two-piecewise logistic regression model
Full size table

Subgroup analyses

Figure 3 presents the results of the subgroup analysis, demonstrating consistent patterns across various subgroups, including sex (male, female), marital status (single, married), education level (junior high school, senior high school, college, postgraduate), and comorbid anxiety status (no, yes). No significant interaction effects were observed in any of these subgroups. However, in relation to suicide attempts, a statistically significant interaction effect was detected (p < 0.001).

Fig. 3
figure 3

Subgroup analysis of the association between TSH and psychotic symptoms. The OR (95% CI) was derived from the Logistic regression model. (Age, sex, education, duration of illness, HAMD, HAMA, A-TG, A-TPO, TC, HDL-c, LDL-c, SBP and DBP were adjusted)

Full size image

Discussion

In this population-based cross-sectional study, the association between serum TSH level and PD was examined after adjusting for covariables. The findings revealed a significant association, indicating that higher serum TSH levels were linked to PD. Furthermore, a non-linear correlation was observed, with an inflection point identified at 4.94 mIU/L. These results remained consistent across various subgroups, including gender, education, marital status, and comorbid anxiety. However, when considering the presence or absence of a suicide attempt, an interaction effect was observed. This highlights the need for further investigation into the associations between TSH levels and suicide attempts in PD patients.

The primary focus of this study was to investigate the relationship between serum TSH levels and PD in FEDN MDD patients. In the treatment of MDD, antidepressant drugs such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, and monoamine oxidase inhibitors are commonly utilized [37]. Additionally, for cases of treatment-resistant depression, augmentation with second-generation antipsychotics and lithium has shown efficacy [38, 39]. Previous research has reported the impact of antidepressant drugs on thyroid function [40,41,42,43,44,45,46]. Consequently, it is plausible that the correlation between TSH levels and PD among FEDN MDD patients may exhibit distinct features compared to patients who have undergone drug treatment.

In our study, we observed a significant association between higher serum TSH levels and PD. This finding is consistent with several previous studies that have also reported a similar conclusion, suggesting that hypothyroidism characterized by elevated serum TSH levels and reduced serum T3 and T4 levels may contribute to the development of psychotic symptoms [24, 25, 47]. Thyroid hormones not only play a significant role in the development of cerebral cortex [48], but also exert an influence on regional cerebral glucose metabolism [49], the glioendocrine system [50], and the catecholaminergic and serotonin (5-HT) systems within the brain [51], collectively impacting an individual’s mental state. Deviation from normal thyroid hormone levels may induce variability in cerebral functions, thereby precipitating manifestations of psychosis. Moreover, thyroid dysfunction observed in PD patients may stem from an augmented release of cortisol triggered by an overactive hypothalamic-pituitary-adrenal (HPA) axis [52]. To further investigate the relationship between TSH and PD, we explored the correlation in a non-linear manner and identified an inflection point at 4.94 mIU/L. Below this threshold, there was no significant evidence of a relationship between serum TSH levels and PD. However, when TSH levels exceeded 4.94 mIU/L, the probability of PD substantially increased by 47% for each unit increase in serum TSH level. It is important to note that the normal range for TSH in our study was defined as 0.27–4.20 mIU/L, and the inflection point of 4.94 mIU/L was 0.74 mIU/L above the upper limit of the normal range. The fact that TSH levels below 4.94 mIU/L, although fluctuating, remained within or close to the normal range can be attributed to the regulatory capacity of our body. Even when certain hormones occasionally deviate from the normal range, our physiological and mental state tends to maintain balance and not exhibit abnormalities. However, when these deviations exceed a certain threshold, abnormalities may manifest and worsen. In our study, although the recommended upper limit of TSH was 4.2 mIU/L, as long as the TSH level remained below 4.94 mIU/L, there was no statistically significant association between TSH and PD. Conversely, when TSH levels exceeded 0.74 mIU/L beyond the upper limit of the normal range, a positive correlation with PD became apparent.

HPT axis operates through a negative feedback regulation mechanism. TSH does not directly affect somatic cells but instead modulates the concentration of thyroid hormones, which act directly on thyroid receptors in the nuclei of target cells, thereby exerting their biological effects. Changes in absolute or relative thyroid hormone concentrations can influence the secretion of thyrotropin-releasing hormone (TRH) in the hypothalamus, thereby regulating the overall HPT axis. Elevated serum TSH levels typically indicate a deficiency in absolute or relative thyroid hormone levels, such as reduced receptor sensitivity. A multicenter European study elucidated that MDD patients comorbid hypothyroidism – characterized as high TSH and low thyroid hormone levels - were more likely to exhibit psychotic features [14]. Fluctuations in thyroid hormone levels have been shown to impact various aspects of brain function, including regional cerebral glucose metabolism [49], the glioendocrine system [50], catecholaminergic system, and the brain serotonin (5-HT) system [51]. These alterations in brain cell function may contribute to the development of depression and the manifestation of psychotic symptoms.

Alternatively, in cases where abnormalities arise within the central endocrine system, serum levels of TSH may exhibit abnormal elevations irrespective of thyroid hormone concentrations. TSH, being directly regulated by TRH, is subject to fluctuations if any disruptions occur in TRH secretion. Additionally, certain pituitary tumors can contribute to excessive TSH secretion, further exacerbating the abnormal elevation of TSH levels. Consequently, the levels of thyroid hormones also increase due to the heightened TSH activity. Previous investigations have established links between thyroid hormone levels and the manifestation of psychotic symptoms [53,54,55,56]. Duval et al. postulated that thyroid dysfunction observed in patients with psychotic disorders may stem from heightened cortisol secretion triggered by an overactive hypothalamic-pituitary-adrenal axis [52]. .

Several limitations should be noted. Firstly, due to its cross-sectional design, the ability to establish causal relationships between TSH and PD is inherently limited. Secondly, variations in TSH testing methods across different hospitals have resulted in the adoption of diverse reference standards. Consequently, caution must be exercised when interpreting the inflection point at 4.94 mIU/L. Thirdly, medication history was obtained through interviews with patients and their family members rather than relying on medical records. This introduces the potential for recall bias and may impact the accuracy of the data. Fourthly, all MDD patients were recruited from the outpatient department of a general hospital in Shanxi Province, China. Therefore, our findings should be extended cautiously to inpatients, community patients, and outpatients from other regions or racial groups. Fifthly, several confounding factors crucial to the study were not collected, such as employment status, family income, and serum TSH level before the onset of MDD. Future studies should impose repetitive examinations of TSH for a better exploration of the relationship between TSH and PD. Furthermore, the analysis of additional thyroid function indicators, including T3, T4, and TRH, could provide further insights into the impact of thyroid function on the development of PD.

Conclusion

Our investigation showed a nonlinear TSH-PD relationship in FEDN MDD patients but differing TSH inflection points between comorbid suicide attempt, thus contributing to effective intervention strategies for psychotic symptoms in depression patients. Notably, we observed a noteworthy positive correlation between serum TSH levels and psychotic symptoms solely when TSH concentrations exceeded the threshold of 4.94 mIU/L.

Data availability

The data are available from the corresponding author on reasonable request.

References

  1. Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, Charlson F, Davis A, Degenhardt L, Dicker D, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;386(9995):743–800.

    Article  Google Scholar 

  2. Huang Y, Wang Y, Wang H, Liu Z, Yu X, Yan J, Yu Y, Kou C, Xu X, Lu J, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6(3):211–24.

    Article  PubMed  Google Scholar 

  3. Dubovsky SL, Ghosh BM, Serotte JC, Cranwell V. Psychotic depression: diagnosis, differential diagnosis, and treatment. Psychother Psychosom. 2021;90(3):160–77.

    Article  PubMed  Google Scholar 

  4. Jääskeläinen E, Juola T, Korpela H, Lehtiniemi H, Nietola M, Korkeila J, Miettunen J. Epidemiology of psychotic depression - systematic review and meta-analysis. Psychol Med. 2018;48(6):905–18.

    Article  PubMed  Google Scholar 

  5. Haley GM, Fine S, Marriage K. Psychotic features in adolescents with major depression. J Am Acad Child Adolesc Psychiatry. 1988;27(4):489–93.

    Article  CAS  PubMed  Google Scholar 

  6. Maj M, Pirozzi R, Magliano L, Fiorillo A, Bartoli L. Phenomenology and prognostic significance of delusions in major depressive disorder: a 10-year prospective follow-up study. J Clin Psychiatry. 2007;68(9):1411–7.

    Article  PubMed  Google Scholar 

  7. Ohayon MM, Schatzberg AF. Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry. 2002;159(11):1855–61.

    Article  PubMed  Google Scholar 

  8. Coryell W. The treatment of psychotic depression. J Clin Psychiatry. 1998;59(Suppl 1):22–7. discussion 28–29.

    PubMed  Google Scholar 

  9. Vythilingam M, Chen J, Bremner JD, Mazure CM, Maciejewski PK, Nelson JC. Psychotic depression and mortality. Am J Psychiatry. 2003;160(3):574–6.

    Article  PubMed  Google Scholar 

  10. Gournellis R, Tournikioti K, Touloumi G, Thomadakis C, Michalopoulou PG, Christodoulou C, Papadopoulou A, Douzenis A. Psychotic (delusional) depression and suicidal attempts: a systematic review and meta-analysis. Acta Psychiatrica Scandinavica. 2018;137(1):18–29.

    Article  CAS  PubMed  Google Scholar 

  11. Paljarvi T, Tiihonen J, Lahteenvuo M, Tanskanen A, Fazel S, Taipale H. Mortality in psychotic depression: 18-year follow-up study. Br J Psychiatry. 2023;222(1):37–43.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Wigman JT, van Nierop M, Vollebergh WA, Lieb R, Beesdo-Baum K, Wittchen HU, van Os J. Evidence that psychotic symptoms are prevalent in disorders of anxiety and depression, impacting on illness onset, risk, and severity–implications for diagnosis and ultra-high risk research. Schizophr Bull. 2012;38(2):247–57.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Fukao A, Takamatsu J, Arishima T, Tanaka M, Kawai T, Okamoto Y, Miyauchi A, Imagawa A. Graves’ disease and mental disorders. J Clin Transl Endocrinol. 2020;19:100207.

    PubMed  Google Scholar 

  14. Fugger G, Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, Zohar J, Montgomery S, Frey R, et al. Comorbid thyroid disease in patients with major depressive disorder - results from the European group for the study of resistant depression (GSRD). Eur Neuropsychopharmacol. 2018;28(6):752–60.

    Article  CAS  PubMed  Google Scholar 

  15. Wong HH, Pang NTP. Deliberate self-harm in a patient with hyperthyroidism with acute psychosis. BMJ Case Rep. 2021;14(10).

  16. Bernstein HG, Keilhoff G, Steiner J. The implications of hypothalamic abnormalities for schizophrenia. Handb Clin Neurol. 2021;182:107–20.

    Article  PubMed  Google Scholar 

  17. Hall RCW. Psychiatric effects of thyroid hormone disturbance. Psychosomatics. 1983;24(1):7–18.

    Article  CAS  PubMed  Google Scholar 

  18. Ozten E, Tufan AE, Cerit C, Sayar GH, Ulubil IY. Delusional parasitosis with hyperthyroidism in an elderly woman: a case report. J Med Case Rep. 2013;7:17.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Gorkhali B, Sharma S, Amatya M, Acharya D, Sharma M. Anxiety and depression among patients with thyroid function disorders. J Nepal Health Res Counc. 2020;18(3):373–8.

    Article  PubMed  Google Scholar 

  20. Ittermann T, Volzke H, Baumeister SE, Appel K, Grabe HJ. Diagnosed thyroid disorders are associated with depression and anxiety. Soc Psychiatry Psychiatr Epidemiol. 2015;50(9):1417–25.

    Article  PubMed  Google Scholar 

  21. Choi KW, Kim Y, Fava M, Mischoulon D, Na EJ, Kim SW, Shin MH, Chung MK, Jeon HJ. Increased morbidity of major depressive disorder after thyroidectomy: a nationwide population-based study in South Korea. Thyroid. 2019;29(12):1713–22.

    Article  PubMed  Google Scholar 

  22. Qiao D, Liu H, Zhang X, Lei L, Sun N, Yang C, Li G, Guo M, Zhang Y, Zhang K, et al. Exploring the potential of thyroid hormones to predict clinical improvements in depressive patients: a machine learning analysis of the real-world based study. J Affect Disord. 2022;299:159–65.

    Article  CAS  PubMed  Google Scholar 

  23. Arem R, Cusi K. Thyroid function testing in psychiatric illness: usefulness and limitations. Trends Endocrinol Metab. 1997;8(7):282–7.

    Article  CAS  PubMed  Google Scholar 

  24. Lipkes C, Haider S, Rashid A, Angarita GA, Riley S. First episode psychosis and pituitary hyperplasia in a patient with untreated Hashimoto’s thyroiditis: a case report. Front Psychiatry. 2022;13:863898.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Todorov L, Ait Boudaoud A, Pascal de Raykeer R, Radu A, Lahlou-Laforet K, Limosin F, Lemogne C, Czernichow S. A case of violent suicide attempt in a context of myxedema psychosis following radioiodine treatment in a patient with Graves’ disease. Case Rep Psychiatry. 2019;2019:4972760.

  26. Ohta H, Inoue S, Hara K, Watanabe A. TSH and PRL, side-effect markers in aripiprazole treatment: adjunctive aripiprazole-induced thyrotropin oversuppression in a young man with schizophrenia. BMJ Case Rep. 2017;2017.

  27. Sakai Y, Iversen V, Reitan SK. FT4 and TSH, relation to diagnoses in an unselected psychiatric acute-ward population, and change during acute psychiatric admission. BMC Psychiatry. 2018;18(1):244.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Cheng P, Wang L, Xu L, Zhou Y, Zhang L, Li W. Factors related to the length of stay for patients with schizophrenia: a retrospective study. Front Psychiatry. 2021;12:818254.

    Article  PubMed  Google Scholar 

  29. Misiak B, Stanczykiewicz B, Wisniewski M, Bartoli F, Carra G, Cavaleri D, Samochowiec J, Jarosz K, Rosinczuk J, Frydecka D. Thyroid hormones in persons with schizophrenia: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2021;111:110402.

    Article  CAS  PubMed  Google Scholar 

  30. Yang R, Zhu F, Yue Y, Lu X, Zhu P, Li Z, Zhao X, Yang X, Zhou Y, Du X. Association between thyroid function and psychotic symptoms in adolescents with major depressive disorder: a large sample sized cross-sectional study in China. Heliyon. 2023;9(6):e16770.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Yang L, Yang X, Yang T, Wu X, Sun P, Zhu Y, Su Y, Gu W, Qiu H, Wang J, et al. The effect of thyroid function on the risk of psychiatric readmission after hospitalization for major depressive disorder. Psychiatry Res. 2021;305:114205.

    Article  PubMed  Google Scholar 

  32. Zhou Y, Li Z, Wang Y, Huang H, Chen W, Dong L, Wu J, Chen J, Miao Y, Qi L, et al. Prevalence and clinical correlates of psychotic depression in first-episode and drug-naive outpatients with major depressive disorder in a Chinese Han population. J Affect Disord. 2020;263:500–6.

    Article  PubMed  Google Scholar 

  33. Melamed SB, Farfel A, Gur S, Krivoy A, Weizman S, Matalon A, Feldhamer I, Hermesh H, Weizman A, Meyerovitch J. Thyroid function assessment before and after diagnosis of schizophrenia: a community-based study. Psychiatry Res. 2020;293:113356.

    Article  CAS  PubMed  Google Scholar 

  34. Yang R, Du X, Li Z, Zhao X, Lyu X, Ye G, Lu X, Zhang G, Li C, Yue Y, et al. Association of subclinical hypothyroidism with anxiety symptom in young first-episode and drug-naive patients with major depressive disorder. Front Psychiatry. 2022;13:920723.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Moustafa AT, Moazzami M, Engel L, Bangert E, Hassanein M, Marzouk S, Kravtsenyuk M, Fung W, Eder L, Su J, et al. Prevalence and metric of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis. Semin Arthritis Rheum. 2020;50(1):84–94.

    Article  PubMed  Google Scholar 

  36. Peng P, Wang Q, Ren H, Zhou Y, Hao Y, Chen S, Wu Q, Li M, Wang Y, Yang Q, et al. Association between thyroid hormones and comorbid psychotic symptoms in patients with first-episode and drug-naïve major depressive disorder. Psychiatry Res. 2023;320:115052.

    Article  CAS  PubMed  Google Scholar 

  37. Mutingwende FP, Kondiah PPD, Ubanako P, Marimuthu T, Choonara YE. Advances in nano-enabled platforms for the treatment of depression. Polymers (Basel). 2021;13(9).

  38. Borbely E, Simon M, Fuchs E, Wiborg O, Czeh B, Helyes Z. Novel drug developmental strategies for treatment-resistant depression. Br J Pharmacol. 2022;179(6):1146–86.

    Article  CAS  PubMed  Google Scholar 

  39. Kverno KS, Mangano E. Treatment-resistant depression: approaches to treatment. J PsychoSoc Nurs Ment Health Serv. 2021;59(9):7–11.

    Article  PubMed  Google Scholar 

  40. Liao H, Rosenthal DS, Kumar SC. Abnormal thyroid function laboratory results caused by selective serotonin reuptake inhibitor (SSRI) antidepressant treatment. Case Rep Psychiatry. 2023;2023:7170564.

  41. Takahashi M, Sawayama E, Sawayama T, Miyaoka H. Reversible paroxetine-induced symptomatic hypothyroidism. Pharmacopsychiatry. 2007;40(5):201–2.

    Article  CAS  PubMed  Google Scholar 

  42. Eker SS, Akkaya C, Ersoy C, Sarandol A, Kirli S. Reversible escitalopram-induced hypothyroidism. Gen Hosp Psychiatry. 2010;32(5):e559555–557.

    Article  Google Scholar 

  43. Mazokopakis EE, Karefilakis CM, Starakis IK. Escitalopram-induced subclinical hypothyroidism. A case report. Horm (Athens). 2012;11(1):101–3.

    Article  Google Scholar 

  44. Lai J, Xu D, Peterson BS, Xu Y, Wei N, Zhang M, Hu S. Reversible fluoxetine-induced hyperthyroidism: a case report. Clin Neuropharmacol. 2016;39(1):60–1.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Martínez Ortiz JJ. Hyperthyroidism secondary to antidepressive treatment with fluoxetine. Anales De Med Interna (Madrid Spain: 1984). 1999;16(11):583–4.

    Google Scholar 

  46. Caye A, Pilz LK, Maia AL, Hidalgo MP, Furukawa TA, Kieling C. The impact of selective serotonin reuptake inhibitors on the thyroid function among patients with major depressive disorder: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2020;33:139–45.

    Article  CAS  PubMed  Google Scholar 

  47. Sardar S, Habib MB, Sukik A, Tanous B, Mohamed S, Tahtouh R, Hamad A, Mohamed MFH. Myxedema psychosis: neuropsychiatric manifestations and rhabdomyolysis unmasking hypothyroidism. Case Rep Psychiatry. 2020;2020:7801953.

  48. Bernal J, Morte B, Diez D. Thyroid hormone regulators in human cerebral cortex development. J Endocrinol. 2022;255(3):R27–36.

    Article  CAS  PubMed  Google Scholar 

  49. Miao Q, Zhang S, Guan YH, Ye HY, Zhang ZY, Zhang QY, Xue RD, Zeng MF, Zuo CT, Li YM. Reversible changes in brain glucose metabolism following thyroid function normalization in hyperthyroidism. AJNR Am J Neuroradiol. 2011;32(6):1034–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Noda M. Possible role of glial cells in the relationship between thyroid dysfunction and mental disorders. Front Cell Neurosci. 2015;9:194.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Bauer M, Heinz A, Whybrow PC. Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain. Mol Psychiatry. 2002;7(2):140–56.

    Article  CAS  PubMed  Google Scholar 

  52. Duval F, Mokrani MC, Monreal-Ortiz JA, Fattah S, Champeval C, Schulz P, Macher JP. Cortisol hypersecretion in unipolar major depression with melancholic and psychotic features: dopaminergic, noradrenergic and thyroid correlates. Psychoneuroendocrinology. 2006;31(7):876–88.

    Article  CAS  PubMed  Google Scholar 

  53. Ishihara Y, Sugawa T, Kaneko H, Hiroshima-Hamanaka K, Amano A, Umakoshi H, Tsuiki M, Kusakabe T, Satoh-Asahara N, Shimatsu A, et al. The delayed diagnosis of thyroid storm in patients with psychosis. Intern Med. 2019;58(15):2195–9.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Bennett B, Mansingh A, Fenton C, Katz J. Graves’ disease presenting with hypomania and paranoia to the acute psychiatry service. BMJ Case Rep. 2021;14(2).

  55. Asif H, Nwachukwu I, Khan A, Rodriguez G, Bahtiyar G. Hyperthyroidism presenting with mania and psychosis: a case report. Cureus. 2022;14(2):e22322.

    PubMed  PubMed Central  Google Scholar 

  56. Sumi Y, Kawahara S, Fujii K, Yamaji M, Nakajima K, Nakamura T, Horikawa O, Fujita Y, Ozeki Y. Case report: impact of hyperthyroidism on psychotic symptoms in schizophrenia comorbid with Graves’ disease. Front Psychiatry. 2023;14:1219049.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank the First Clinical Medical College, Shanxi Medical University for the supports.

Funding

This work was supported by the Suzhou Gusu Health Talents Scientific Research Project (GSWS2021053 and GSWS2020097), Medical research key project of Jiangsu Provincial Health Commission (K2023015) and the Suzhou clinical Medical Center for mood disorders (Szlcyxzx202109).

Author information

Author notes

  1. Ruchang Yang and Zhe Li contribute equally to this work and share first authorship.

Authors and Affiliations

  1. Suzhou Medical College of Soochow University, Suzhou, China

    Ruchang Yang, Yingzhao Zhu, Yuxuan Wu & Xiangdong Du

  2. Suzhou Guangji Hospital, The Affiliated Guangji Hospital of Soochow University, Suzhou, China

    Ruchang Yang, Zhe Li, Yingzhao Zhu, Yuxuan Wu, Xinchuan Lu, Xueli Zhao & Xiangdong Du

  3. Nanjing Meishan Hospital, Nanjing, China

    Junjun Liu

  4. CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China

    Xiangyang Zhang

Authors
  1. Ruchang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhe Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yingzhao Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuxuan Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xinchuan Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xueli Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Junjun Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiangdong Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xiangyang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Ruchang Yang and Zhe Li wrote the main manuscript text. Yingzhao Zhu and Yuxuan Wu prepared Tables 1, 2 and 3. Xinchuan Lu and Xueli Zhao prepared Figs. 1, 2 and 3. Junjun Liu made the statistical analysis. Xiangdong Du and Xiangyang Zhang revised the manuscript. All authors reviewed the manuscript.

Corresponding authors

Correspondence to Xiangdong Du or Xiangyang Zhang.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the medical ethics committee at the First Hospital of Shanxi Medical University. Informed consent was obtained from all subjects and/or their legal guardian(s).

Consent for publication

Not Applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, R., Li, Z., Zhu, Y. et al. Non-linear relationship between TSH and psychotic symptoms on first episode and drug naïve major depressive disorder patients: a large sample sized cross-sectional study in China. BMC Psychiatry 24, 413 (2024). https://doi.org/10.1186/s12888-024-05860-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12888-024-05860-7

Keywords

BMC Psychiatry

ISSN: 1471-244X

Contact us